Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by funky99on Jul 14, 2016 10:10am

105 Views

Post# 25051868

Private placement insiders

Interesting to see Chair of the Board, VP Business Development and Chief Scientific Officier taking part of the PP. Number of placees: 40 placees Insiders: -Scott Curtis, 50,000 shares; -Walt Macnee, one million shares; -John Wallace, 100,000 shares https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aATE-2389434&symbol=ATE®ion=C I think this bodes well for the future.

Bullboard Posts

Day trading vs. swing trading strategies for small-cap stocks